C. Lips

The outcome of radioiodine treatment in Graves ’ disease is determined by the 131 I turnover rate and by the timing of 131 I uptake measurements

J. W. Isselt, P. Rijk, H. Wijnne, 2000 .

The success rate of I-131 ablation in differentiated thyroid cancer: comparison of uptake-related and fixed-dose strategies.

J. Smit, M. Stokkel, F. Verburg, 2007, European journal of endocrinology.

Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy

B. de Keizer, H. Koppeschaar, J. D. de Klerk, 2000, Nuclear medicine communications.

Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science?

J. V. van Isselt, J. D. de Klerk, C. Lips, 2007, European Journal of Nuclear Medicine and Molecular Imaging.

Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma.

P. V. van Rijk, E. Lentjes, P. L. Jager, 2005, The Journal of clinical endocrinology and metabolism.

CLINICAL CASE SEMINAR Repeated ( 131 I)Metaiodobenzylguanidine Therapy in Two Patients with Malignant Pheochromocytoma

E. Lentjes, P. L. Jager, M. Lam, 2005 .

Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients.

B. de Keizer, F. Verburg, P. Zelissen, 2005, European journal of endocrinology.

Value of diagnostic radioiodine scintigraphy and thyroglobulin measurements after rhTSH injection

B. de Keizer, E. Lentjes, F. Verburg, 2008, Nuklearmedizin.

Persistent Disease in Patients with Papillary Thyroid Carcinoma and Lymph Node Metastases After Surgery and Iodine-131 Ablation

M. Lam, F. Verburg, J. W. Isselt, 2007, World Journal of Surgery.